LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Syphilis Assay Improves Lab Efficiency and Reduces Costs Through Earlier Disease Detection

By LabMedica International staff writers
Posted on 30 Aug 2024
Print article
Image: The VITROS Syphilis Assay has received FDA 510(k) clearance (Photo courtesy of QuidelOrtho)
Image: The VITROS Syphilis Assay has received FDA 510(k) clearance (Photo courtesy of QuidelOrtho)

The prevalence of syphilis and other sexually transmitted infections (STIs) in the U.S. has seen a notable increase, with more than 176,000 new syphilis cases reported annually—a 36% rise in cases of primary and secondary syphilis since 2021. This surge underscores the urgent need for comprehensive and accessible diagnostic tools. In response, the Centers for Disease Control and Prevention recommends using both nontreponemal and treponemal serologic tests together to diagnose syphilis effectively. Now, a newly approved syphilis assay can provide timely and accurate diagnoses, which are vital for the effective treatment and management of the disease.

QuidelOrtho Corporation (San Diego, CA, USA) has obtained U.S. Food and Drug Administration (FDA) 510(k) clearance for its VITROS syphilis assay as part of its menu. This assay, designed for use with the automated VITROS 3600, 5600, and XT 7600 systems, qualitatively determines the presence of total antibodies (IgG and IgM) to Treponema pallidum (TP)-specific antigens in human serum and plasma. The detection of TP-specific antibodies, when evaluated alongside non-treponemal test results and clinical assessments, assists in diagnosing syphilis. The VITROS syphilis assay is not intended for blood and tissue donor screening. With this FDA clearance, the VITROS syphilis assay is now available worldwide wherever QuidelOrtho products are sold.

“As an in-demand assay for a common STI, we are pleased to offer the VITROS syphilis assay, bolstering QuidelOrtho’s infectious disease test portfolio in the U.S.,” said Bryan Hanson, Senior Vice President, President North American Commercial Operations at QuidelOrtho. “Not only does this important assay improve laboratory efficiency by allowing labs to follow the CDC’s reverse testing algorithm for syphilis screening, it also reduces costs by providing earlier disease detection, thereby reducing the need to refer tests to outside labs.”

“With an increased national incidence of syphilis and other STIs, having a quick and easy way to test in various healthcare settings is essential,” said Lily Li, Senior Director, Medical Scientific & Clinical Affairs, QuidelOrtho. “The CDC Morbidity and Mortality Weekly Report, updated in February 2024, recommends that both nontreponemal and treponemal serologic tests be used in conjunction to aid in the diagnosis of syphilis.”

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV-1 Test
HIV-1 Real Time RT-PCR Kit
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.